Related Experiment Video
Updated: Aug 7, 2026
12:04
The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
Published on: November 1, 2015
Nemaline Myopathy in Systemic Lupus Erythematosus
Ran Cui1, Xing-Hua Luan2, Sheng-Ming Dai1
1Department of Rheumatology and Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
European Journal of Rheumatology
|August 6, 2026
Summary
Sporadic late-onset nemaline myopathy (SLONM), a rare muscle disorder, was successfully treated with immunotherapy in a patient with systemic lupus erythematosus. This case highlights a potential treatment avenue for SLONM linked to autoimmune conditions.
Area of Science:
- Neurology
- Rheumatology
- Immunology
Background:
- Sporadic late-onset nemaline myopathy (SLONM) is a rare neuromuscular disorder characterized by nemaline rod accumulation in muscle fibers.
- The underlying pathophysiology of SLONM remains unclear, with potential links to autoimmune processes and hematological malignancies.
- Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with diverse clinical manifestations.
Purpose of the Study:
- To present a case of SLONM associated with SLE.
- To evaluate the efficacy of immunotherapy in managing SLONM in the context of SLE.
Main Methods:
- A case report detailing a patient diagnosed with SLONM and SLE.
- Clinical assessment and response to immunotherapy were monitored.
Main Results:
- The patient with SLONM and SLE demonstrated a favorable clinical response to immunotherapy.
- This suggests a potential benefit of immunotherapy in managing SLONM when co-occurring with autoimmune diseases like SLE.
Conclusions:
- SLONM can be associated with systemic autoimmune diseases such as SLE.
- Immunotherapy may represent a viable treatment option for SLONM in patients with concurrent autoimmune conditions.
- Further research is warranted to explore the immunopathogenesis of SLONM and its therapeutic implications.
Related Concept Videos
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:11Alterations in Muscle Tone lll
Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
01:15Myasthenia Gravis: Diagnostic Tests
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
01:28Disorders of the Skeletal Muscle
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...